Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01689974 | Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma | terminated | Phase 2 | 10 | NYU Langone HealthOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT01264874 | MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients(MelaViD) | terminated | Phase 3 | 150 | European Institute of OncologyOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT01721603 | Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets | terminated | Phase 2 | 2 | University of California, San FranciscoOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT01984892 | Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)(Hiltonol) | terminated | Phase 2 | 8 | Nina BhardwajOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT01740401 | CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma | terminated | Phase 2 | 10 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT01495988 | Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma | terminated | Phase 2 | 10 | Melanoma Research Foundation Breakthrough ConsortiumOTHER | 1 | Oct 24, 2017 | clinicaltrials |
| NCT01009515 | Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma | terminated | Phase 2 | 19 | New Mexico Cancer Research AllianceOTHER | 1 | Oct 18, 2017 | clinicaltrials |
| NCT02111863 | Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Sep 19, 2017 | clinicaltrials |
| NCT01696045 | Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma | terminated | Phase 2 | 14 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 29, 2017 | clinicaltrials |
| NCT01138410 | Study of a DNA Immunotherapy to Treat Melanoma | terminated | Phase 1 / Phase 2 | 35 | Scancell LtdINDUSTRY | 1 | Aug 21, 2017 | clinicaltrials |
| NCT01042366 | Dendritic Cells (DC) Vaccine for Metastatic Melanoma | terminated | Phase 2 | 16 | John KirkwoodOTHER | 1 | Aug 16, 2017 | clinicaltrials |
| NCT00871533 | Pilot Study of IFN α2b for Melanoma Patients | terminated | Early Phase 1 | 50 | University of PittsburghOTHER | 1 | Aug 4, 2017 | clinicaltrials |
| NCT01271907 | Drosophila-generated CTL | terminated | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2017 | clinicaltrials |
| NCT01067066 | A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma | terminated | Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT00849875 | A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients | terminated | Phase 2 | 48 | GlaxoSmithKlineINDUSTRY | 2 | Jul 12, 2017 | clinicaltrials |
| NCT00925132 | Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat | terminated | Phase 1 / Phase 2 | 39 | University of IowaOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01701037 | Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery | terminated | Phase 2 | 13 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 23, 2017 | clinicaltrials |
| NCT01409174 | IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma | terminated | Phase 1 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT01586195 | Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E | terminated | Phase 2 | 31 | Genentech, Inc.INDUSTRY | 1 | May 25, 2017 | clinicaltrials |
| NCT02236546 | FDG-PET in Advanced Melanoma | terminated | N/A | 3 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 13, 2017 | clinicaltrials |
| NCT01551693 | STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma | terminated | Phase 2 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 12, 2017 | clinicaltrials |
| NCT01754376 | Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma | terminated | Phase 2 | 6 | Massachusetts General HospitalOTHER | 1 | Apr 12, 2017 | clinicaltrials |
| NCT02413827 | A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma | terminated | Phase 1 / Phase 2 | 9 | Celldex TherapeuticsINDUSTRY | 1 | Apr 7, 2017 | clinicaltrials |
| NCT01611675 | Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma | terminated | Phase 1 | 3 | Massachusetts General HospitalOTHER | 1 | Apr 6, 2017 | clinicaltrials |
| NCT01026324 | Dinaciclib in Treating Patients With Stage III-IV Melanoma | terminated | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2017 | clinicaltrials |
| NCT00707161 | Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma | terminated | Phase 2 | 6 | University of UtahOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT00482911 | Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma | terminated | Phase 2 | 12 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 27, 2017 | clinicaltrials |
| NCT00601861 | Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer | terminated | Phase 2 | 1 | Novo Nordisk A/SINDUSTRY | 1 | Mar 1, 2017 | clinicaltrials |
| NCT01705392 | Bevacizumab vs Dacarbazine in Metastatic Melanoma | terminated | Phase 2 | 2 | Haukeland University HospitalOTHER | 1 | Feb 24, 2017 | clinicaltrials |
| NCT00550654 | Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain | terminated | Phase 2 | 1 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jan 13, 2017 | clinicaltrials |
| NCT01820364 | LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma(LOGIC) | terminated | Phase 2 | 15 | Array BioPharmaINDUSTRY | 6 | Jan 9, 2017 | clinicaltrials |
| NCT01984255 | A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients | terminated | Phase 1 | 3 | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 29, 2016 | clinicaltrials |
| NCT00977145 | Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma(Mel 51) | terminated | Phase 1 | 11 | Craig L Slingluff, JrOTHER | 1 | Dec 16, 2016 | clinicaltrials |
| NCT00068666 | Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System | terminated | Phase 2 | 41 | Alliance for Clinical Trials in OncologyOTHER | 1 | Dec 15, 2016 | clinicaltrials |
| NCT01888081 | A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma | terminated | Phase 1 / Phase 2 | 2 | Virogen Biotechnology Inc.INDUSTRY | 1 | Nov 23, 2016 | clinicaltrials |
| NCT01950195 | SRS (Stereotactic Radiosurgery) Plus Ipilimumab | terminated | Phase 1 | 4 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 15, 2016 | clinicaltrials |
| NCT01973608 | MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma | terminated | Phase 2 | 12 | EMD SeronoINDUSTRY | 1 | Oct 31, 2016 | clinicaltrials |
| NCT01039844 | Study of Weekly LOC-paclitaxel Injection for Melanoma | terminated | Phase 1 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 27, 2016 | clinicaltrials |
| NCT01307618 | Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Oct 24, 2016 | clinicaltrials |
| NCT01519323 | BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations | terminated | Phase 1 | 6 | Hoffmann-La RocheINDUSTRY | 10 | Oct 10, 2016 | clinicaltrials |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | terminated | Phase 1 | 155 | Mirna Therapeutics, Inc.INDUSTRY | 2 | Sep 27, 2016 | clinicaltrials |
| NCT01777776 | Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. | terminated | Phase 1 / Phase 2 | 28 | Array BioPharmaINDUSTRY | 4 | Sep 13, 2016 | clinicaltrials |
| NCT01092728 | Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma | terminated | Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 5, 2016 | clinicaltrials |
| NCT01082887 | A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg) | terminated | Phase 1 / Phase 2 | 18 | Nantes University HospitalOTHER | 1 | Aug 8, 2016 | clinicaltrials |
| NCT00724841 | A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 1 | Gemin XINDUSTRY | 1 | Jul 22, 2016 | clinicaltrials |
| NCT01468818 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | terminated | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Jun 27, 2016 | clinicaltrials |
| NCT02062359 | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2016 | clinicaltrials |
| NCT01120275 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma | terminated | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Jun 14, 2016 | clinicaltrials |
| NCT01557114 | Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma(Mel-Ipi-Rx) | terminated | Phase 1 | 19 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jun 9, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Feb 23, 2018source: clinicaltrials